IMR Press / JIN / Volume 22 / Issue 2 / DOI: 10.31083/j.jin2202049
Open Access Original Research
Concentration of Apoptotic Factors in Bronchoalveolar Lavage Fluid, as Potential Brain-Lung Oxygen Relationship, Correspond to the Severity of Brain Injury
Show Less
1 Department of Anaesthesiology, Intensive Care Medical University of Lublin, 20-059 Lublin, Poland
2 Collegium Medicum, Department of Surgical Medicine with the Laboratory of Medical Genetics, Jan Kochanowski University, 25-369 Kielce, Poland
3 Anaesthesia and Intensive Care, Policlinico San Martino, Deputy of the Neurointensive Care Section of European Society of Intensive Care Medicine, 16122 Genova, Italy
4 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Genova, Poland
5 Department of Physiotherapy, Medical University of Lublin, 20-059 Szczecin, Poland
*Correspondence: (Dorota Siwicka-Gieroba); (Chiara Robba)
J. Integr. Neurosci. 2023, 22(2), 49;
Submitted: 13 October 2022 | Revised: 24 December 2022 | Accepted: 28 December 2022 | Published: 6 March 2023
(This article belongs to the Special Issue Hypoxia and Brain Function)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Background: The mechanism of acute brain injury initiates a cascade of consequences which can directly cause lung damage, and this can contribute to poor neurological outcomes. The aim of this study was to evaluate concentration of different apoptotic molecules in the bronchoalveolar lavage fluid (BALF) in patients after severe brain injury and to correlate them with selected clinical variables and mortality. Methods: Patients with brain injury receiving BALF operation were included in the study. BALF samples were collected within the first 6–8 hours after traumatic brain injury (A) and at days 3 (B) and 7 (C) after admission to the intensive care unit (ICU). Changes in the BALF nuclear-encoded protein (Bax), apoptotic regulatory protein (Bcl-2), pro-apoptotic protein (p53) and its upregulated modulator (PUMA), apoptotic protease factor 1 (APAF-1), Bcl-2 associated agonist of cell death (BAD) and caspase-activated DNase (CAD) were analysed. These values were correlated with the selected oxygenation parameters, Rotterdam computed tomography (CT) score, the Glasgow Coma Score and 28-day mortality. Results: We found a significant increase in the concentration of selected apoptotic factors at admission (A), at day 3 (B) and day 7 (C) after severe brain damage contrasted with baseline level A (p < 0.001, separately). That concentration of selected apoptotic factors was significantly correlated with the severity of the injury and mortality. Conclusions: Activation of different apoptotic pathways seems to be an important process occurring in the lungs of patients in the early phases after severe brain trauma. Levels of apoptotic factors in the BALF correlates with the severity of brain injury.

brain injuries
brai-lung crosstalk
1. Introduction

Clinical and experimental findings demonstrate the essential role of isolated acute brain injury in peripheral organ and systems failure. The mechanism of acute brain injury initiates a cascade of consequences, which leads to systemic disturbances and poor outcomes [1]. Brain-lung crosstalk is a crucial complex between the brain and lungs, involving various pathophysiological mechanisms [2]. Central nervous system ischemia is one of the crucial mechanism of secondary injury in different types of neurocritical damages [3]. Oxygen therapy in brain injured patients should be considered carefully because hyperoxemia is connected with worse outcome [4, 5]. Recent data suggest that formation of reactive oxygen species (ROS), alterations metabolic function disturbances, hyperoxia-induced vasoconstriction are the main reason of poorer otcome. In opposite, some studies hyperoxemia exposure even some benefit [6, 7].

Previously, Minabres et al. [8] documented that a apoptosis activation was an independent factor corresponded with 6-months mortality and poor outcome in severe brain injury. However, the molecular mechanisms of lung damage mediated by brain trauma are still under debate. Our previous investigations showed the increase of caspase 3, 6, 8, 9 and 12 concentrations in the BALF of patients after severe brain damage [9]. Therefore we decided to invesigate the concentrations of selected proteins involved in the induction of apoptosis.

The primary aim of this study was to evaluate concentration of different apoptotic factors in bronchoalveolar lavage fluid (BALF) after isolated severe brain damage. Secondary aims include to assess the conection between the activation of proteins involved in apoptosis with selected clinical variables and mortality.

We hypothesise that the occurrence of isolated brain injury may lead to an activation of apoptotic pathways in lung, thus representing an evolving lung injury mediated by brain-lung crosstalk, and that the apoptotic proteins detected in BALF may be connected with the severity of injury.

2. Materials and Methods
2.1 Study Settings

This prospective study was conducted in accordance with the Declaration of Helsinki and applicable regulatory requirements approved by the Bioethics Committee of the Medical University in Lublin, Poland (KE-0254/210/2017).

Inclusion criteria included adult patients (age 18), who were hospitalized for severe, isolated traumatic brain injury (TBI) and admitted to the intensive care unit (ICU). Patients on mechanical ventilation support during the initial 24 h in the ICU and with isolated brain injury, who had a head computed tomography (CT) scan were included in the study (Fig. 1).

Fig. 1.

Flowchart of patient inclusion and exclusion. Figure showed exclusion of 73 patients during intensive care from the study: missing data, lung injury, respiratory bacterial contamination and those who died prior to 7 days. The final study sample included 40 patients.

Diagnoses of brain damage were defined according to the Acute Physiology and Chronic Health Evaluation III (APACHE III) and the International Classification of Diseases and Related Health Problems, 10th Revision [10]. Brain injury was classified basing on radiological findings at admission CT.

Exclusion criteria were patients aged under 18 years, pregnancy, patients with history of pulmonary and hepatorenal chronic diseases, with neoplastic diseases and drug-intoxication and prior transplant recipients.

2.2 ICU Monitoring Protocol and Treatment

All patients with severe brain injury between January 2018 and December 2020 included in the study were sedated and treated according to the latest Brain Trauma Foundation guidelines [11]. Our monitoring and treatment methods have been formerly documented [12].

All brain injured patients were mechanical ventilated according to strategies described [1, 13]. The PEEP levels (between 5–8 cmH2O) were adapt to preserve values of minimal oxygenation (SatO2) between 94–97%, and PaO2>70 mmHg.

Intracranial space-occupying lesions (subdural and/or epidural hematomas), were removed via craniotomy or craniectomy, at the neurosurgeon’s discretion.

2.3 Data Collection

BALF from patients was collected within 6–8 hours after isolated brain injury (A) and at day 3 (B) and 7 (C) after initial damage. A flexible bronchoscope was introduced into the airway and lavages from the middle lobes were achived using sterile saline (20 mL per lavage). The collected BALF was processed in a standard manner according to described protocols [14]. The collected two millilitres of BALF were centrifuged to separate the fluid from the cells (1900 rpm/10 min/room temperature), and the supernatant was stored at –80 °C for further study.

2.4 Determination of pro-and Antiapoptotic Factor Concentrations

Detection of proapoptotic and antiapoptotic factors concentrations was undertaken by an Enzyme-linked Immunosorbent Assay Kit according to the original instructions of the manufacturer, Cloud-Clone Corp. (Houston, TX, USA). The samples were analysed on microplate reader at 450 nm. A standard curve was created by plotting the absorbance of each standard vs. the suitable standard concentration (Table 1).

Table 1.Detection range and sensitivities of apoptotic factor assays.
Apoptotic factors Detection range Sensitivities of the assays (less than)
Caspase Activated DNase (CAD) 156–10 ng/mL 0.054 ng/mL
Tumour protein p53 (TP53) 78–5.000 pg/mL 27 pg/mL
B-Cell Leukaemia/Lymphoma 2 (Bcl-2) 0.156–10 ng/mL 0.061 ng/mL
Bcl2 Associated X Protein (BAX) 0.78–50 ng/mL 0.30 ng/mL
p53 Upregulated Modulator of Apoptosis (PUMA) 0.156–10 ng/mL 0.056 ng/mL
Apoptotic Peptidase Activating Factor 1 (APAF1) 0.156–10 ng/mL 0.057 ng/mL
Bcl2 Associated Death Promoter (BAD) 70–5.000 pg/mL 31 pg/mL
2.5 Study Variables

Primary clinical variables were blood analyses, selected inflammatory parameters, oxygenation and blood gas analyses, extravascular lung water (EVLWI) and pulmonary vascular permeability index (PVPI). We categorized PaO2 values as normoxaemia (PaO2 75–100 mmHg), hypoxemia (PaO2<75 mmHg) and hyperoxaemia (PaO2 >100 mmHg).

Secondary study variables were correlated between apoptotic markers concentration and selected scores systems as Glasgow Coma Score (GCS), Rotterdam computed tomography score (CTS) care system. Data on mortality were received on day 28.

2.6 Statistical Analyses

The appropriate statistical tests were selected after normal distribution testing by plotting and the Shapiro–Wilk test. Continuous variables are analysed using ANOVA analysis of variance with repeated measures. Multiple comparisons between the means of measurements were made using Tukey’s HSD (honestly significant difference) test. The connections between the received values of selected medical indicators on three dates of measurements were correlated using Pearson’s and Spearman’s correlation coefficient. Cox regression was used to calculate the hazard ratio and 95% confidence interval. A p-value of <0.05 cut off was considered as statistically significant. Statistical analysis was performed using Statistical Package for the Social Sciences (version 26, IBM SPSS, Chicago, IL, USA) software.

3. Results
3.1 Characteristics of the Patients

The study included 113 adult ICU treated patients with isolated severe brain injury. We excluded 73 patients during intensive care from the study, 31 patients did not meet the inclusion criteria (because of severe lung diseases, acute heart failure with pulmonary oedema, lung contusions) (Fig. 1, Table 2).

Table 2.Patient characteristics at admission (A), at day 3 (B) and day 7 (C), presented by mean value (SD).
General Survivors Non-survivors
Age 46 (15) 44 (17) 47 (12)
CT findings
Marshal II 5 5 0
Marshal III 3 3 0
Marshal IV 8 6 2
Marshal V 19 10 9
Marshal VI 5 0 5
Clinical examination
Glasgow Coma Score 4.5 (1.33) 5.29 (1.12) 3.3 (0.47)
APACHE II score 22 (5) 21 (6) 24 (5)
Rotterdam CT scale 4 (1) 4 (1) 5 (1)
Lactate during admission* 3.2 (1.37) 2.85 (1.35) 3.73 (1.27)
CRP A 144.15 (59.19) 129.29 (57.88) 166.44 (55.59)
CRP B 187.80 (46.15) 174.29 (39.31) 208.06 (49.37)
CRP C 196.08 (69.68) 172.83 (56.12) 230.94 (75.05)
ICU length of stay* 32 (43) 45 (51) 14 (4)
Ventilation days* 26 (34) 36 (41) 13 (4)
PaO2/FiO2 ratio at admission* 345.9 (116.3) 304.7 (76.3) 407.6 (139.6)
mean PaO2 A 119.93 (38.27) 102.05 (15.8) 146.75 (46.35)
mean PaO2 B 87.35 (8.06) 86.45 (8.78) 88.7 (6.9)
mean PaO2 C 85.17 (10.71) 85.59 (10.05) 84.54 (11.94)

The Marshall score is presented by number of patients. ICU, intensive care unit; FiO2, fraction of inspired oxygen; PaO2, partial pressure of oxygen, * statistically significant difference between survivors and non-survivors.

Finally 40 patients, between 18–76 years old, 24 men and 16 women, were included in study (Fig. 2).

Fig. 2.

Age distribution of the patients.

The C-reactive protein were higher at admission in group of non-survivors compared survivors (p = 0.051, F = 4.079), as well as at day 3 and day 7 (p = 0.021, F = 5.769 and p = 0.008, F = 7.845 respectively). Lactate levels were also significantly higher in non-surviving patients (p = 0.046, F = 4.257) compared to survivors.

Non-survivors presented a statistically significant lower value of GCS (p < 0.01, F = 44.109) and a statistically significant higher Rotterdam CT score (p < 0.01, F = 51.282). There was no statistically significant difference in APACHE II scores at admission between the surviving and non-surviving patients (p = 0.113). In addition there were no significant findings between all apoptotic factors and performance of surgical procedures (p > 0.05).

3.2 Oxygen Parameters

The analyses showed that in the non-surviving group of patients, the fraction of inspired oxygen (FiO2) at admission was significant higher (p = 0.002, F = 11.232) compared to survivors. Importantly, the mean values of FiO2 at admission, day 3 (B) and day 7 (C) were higher in non-survivors (p < 0.001, F = 15.294; p = 0.001, F = 12.106 and p <0.001, F = 16.132 respectively).

In addition, mean PaO2 at admission was significantly lower in surviving patients (p < 0.001, F = 19.196). There was no significant difference between groups compared to mean PaO2 at day 3 and day 7 (p > 0.05) (Fig. 3).

Fig. 3.

Mean value of partial pressure of oxygen (PaO2) at admission (A), day 3 (B) and day 7th (C), in survivors and non-survivors. The results documented that in the surviving group of patients, PaO2 at admission to the ICU was significantly lower than in non-surviving patients; * p < 0.001. There was no significant difference between groups compared to mean PaO2 at day 3 and day 7 (p > 0.05). ° Outliers value.

Patients with a higher mean value of PaO2 at admission had significantly (p < 0.001) shorter survival times than those with lower PaO2mean values (hazard ratio 4.410, 95% confidence interval (CI) 1.969; 9.875) (Fig. 4).

Fig. 4.

28 day mortality. Cox regression showed that patients with higher mean PaO2 values at admission had significantly (p < 0.001) shorter survival times than those with lower mean PaO2 values (hazard ratio 4.410, 95% CI 1.969; 9.875). There were no significant observations regarding mean PaO2 at day 3 and day 7.

3.3 Concentration of Selected Apoptic Factors Expression Levels, in BALF of Brain Injured Patients at Different Timepoints

The statistically significant increase of selected apoptotic factors such as p53 (0.037), BAX (p = 0.021), PUMA (p < 0.001), APAF-1 (p < 0.001), BAD (p = 0.05), CAD (p = 0.002) between 3 timepoints A, B, C were observed. There was no statistical increase of Bcl-2 between timepoints A and C (p = 0.171).

Importantly, in patients who died, the elevation of selected apoptotic proteins such as BAX (Mann-Whitney U = 1, η2 = 0.45, p = 0.003), p53 (U = 0, η2 = 0.48, p = 0.002), PUMA (U = 6, η2 = 0.32, p = 0.014), APAF-1 (U = 0, η2 = 0.48 p = 0.002), BAD (U = 2, η2 = 0.42, p = 0.005) and CAD (U = 0, η2 = 0.49, p = 0.002) were higher at third (B) and seventh (C) day.

Pearson’s correlation with regression analysis documented that concentrations of BAD (p < 0.001, r = –0.662), CAD (p < 0.001; r = –0.579 and r = –0.602) at day 3 and at day 7 and PUMA (p < 0.01, r = –0.715), p53 (p < 0.01; r = –0.619), APAF-1 (p < 0.01, r = –0.623), BAX (p < 0.01; r = –0.585) and Bcl-2 (p <0.01; r = –0.523) at day 7 were significantly associated with the Glasgow Coma Score at admission.

Statistically significant lower GCS scores (3–4 points) were observed in patients with higher activation of selected apoptotic factors at day 7 (BAX p < 0.01; Bcl-2 p = 0.01, p53, PUMA, APAF-1, BAD and CAD p < 0.01 respectively), especially in the non-survivor group.

In addition, internally in the survivor group there was no association between GCS at admission and an increase of selected apoptotic factors at day 3 and day 7 (p > 0.05).

Importantly, in patients with worse injury (scores of 5–6) assessed on the Rotterdam CT scale at admission, the elevation of factors, in particular BAX (p < 0.001), Bcl-2 (p < 0.05), p53, PUMA, APAF-1, BAD, CAD (p < 0.01 respectively) was significantly elevated at timepoints B and C (Fig. 5).

Fig. 5.

Activation of selected apoptotic factors in BALF and severity of damage according to Rotterdam CT score. *p < 0.001 BALF, bronchoalveolar fluid; CT, computed tomography; FiO2, fraction of inspired oxygen; ** significant change, ° Outliers value.

3.4 Correlation between Activation of Apoptotic Factors in BALF of Brain Injured Patients and Selected Clinical Variables

The results of Spearman’s rho correlation showed a significant statistical association between CRP in patients with more severe injury and activation of apoptotic factors in BALF such as PUMA (at admission, p = 0.007), BAX, p53, PUMA, APAF-1 and CAD at day 3 (p = 0.046; p < 0.05; p < 0.05; p = 0.015; p = 0.016, respectively) and APAF-1, BAX, p53 at day 7 (p = 0.034; p = 0.046; p = 0.01 respectively). Finally, the level of extravascular lung water index (ELWI) was significantly and positively associated with the growth of selected apoptotic factors, except for the Bcl-2 protein (Table 3).

Table 3.Correlation between activation of apoptotic factors in selected timepoints and EVLW and PVPI in brain injured patients.
Extravascular lung water Pulmonary vascular permeability index
BAX Spearman’s rho 0.39 0.45 0.31 0.39 0.36 0.30
p 0.012 0.004 0.049 0.014 0.023 0.059
Bcl-2 Spearman’s rho 0.10 0.10 0.13 0.23 0.19 0.11
p 0.557 0.548 0.421 0.159 0.253 0.507
p53 Spearman’s rho 0.33 0.51 0.48 0.50 0.26 0.23
p 0.039 <0.001 0.002 <0.001 0.107 0.146
PUMA Spearman’s rho 0.54 0.63 0.57 0.58 0.52 0.47
p <0.001 <0.001 <0.001 <0.001 <0.001 0.002
APAF-1 Spearman’s rho 0.46 0.57 0.56 0.64 0.26 0.23
p 0.003 <0.001 <0.001 <0.001 0.101 0.161
BAD Spearman’s rho 0.42 0.60 0.49 0.51 0.17 0.31
p 0.006 <0.001 0.001 <0.001 0.282 0.049
CAD Spearman’s rho 0.49 0.66 0.53 0.61 0.36 0.36
p 0.001 <0.001 <0.001 <0.001 0.023 0.024

It follows that the higher level of ELWI at admission (A), day 3 (B) and 7 (C) corresponded with the greater activation of apoptotic proteins. Statistical significance is marked in bold type. On day 3 (B), PVPI was positively related to BAX, CAD (p = 0.023 respectively; moderate relationship) and PUMA (p < 0.001; strong relationship) proteins increased. Statistically significant correlations were also found between PVPI measured on day 7 (C) and the increase in PUMA, BAD and CAD proteins (p = 0.002; p = 0.049; p = 0.024 accordingly) Moreover, a close to statistical significance was observed (p = 0.059) between PVPI at day 7th (C) and the increase in BAX protein. In summary, the results show that the high PVPI values correlate with a greater increase in selected proteins in BALF.

APAF-1, Apoptotic Peptidase Activating Factor 1; BAD, Bcl2 Associated Death Promoter; BAX, Bcl2 Associated X Protein; Bcl-2, B-Cell Leukaemia/Lymphoma; CAD, Caspase Activated DNase; ELWI, extravascular lung water; PVPI, pulmonary vascular permeability index; PUMA, p53 Upregulated Modulator of Apoptosis; p53, Tumour protein p53.

The value of PVPI at admission was positively correlated with an increase in BAX protein (p = 0.014; moderate relationship) and an increase in p53, PUMA, APAF1, BAD and CAD proteins (p < 0.001 respectively; strong relationships) (Table 3).

There were no significant statistical findings between apoptotic proteins levels at different timepoints and clinical variables such as, neutrophil-to-lymphocyte ratio, gender, d-dimers, or Apache II score at admission.

3.5 Correlation between Elevation of Apoptotic Factors in BALF of Brain Injured Patients and 28-Day Mortality

Considering 28-day mortality, higher activation of apoptotic proteins such as p53, PUMA, BAX, Bcl-2, APAF-1, BAD, CAD in BALF were documented in patients who died (p < 0.001). There was no significant association between 28-day mortality and Bcl-2 elevation (Fig. 6).

Fig. 6.

Activation of selected apoptotic proteins in BALF according to outcome. ***p < 0.001; **p < 0.01. ° Outliers value.

4. Discussion
4.1 Key Findings

The novelty of this study is the evaluation of the spectrum of apoptotic proteins in BALF after brain injury.

This study shows significant changes in selected apoptotic proteins levels in brain injury patients and documents that different pathways of apoptosis seem to be activated in the respiratory system after brain injury. The apoptotic proteins found in BALF in the 6–8 hours after injury and the increase of these markers over the first 7 days indicate an activated processes of destruction and apoptosis in the respiratory tract over external, internal and oxidative stress pathways.

As far as we know, this is the first human study documenting the status of pro- and antiapoptotic proteins in BALF after brain damage according to severity of injury. In addition, this study presented a significant correlation between oxygen status, apoptotic proteins concentrations in BALF and 28-day mortality.

4.2 Relationship with Previous Studies

The relationship between lung and brain damage remains obscure. Inflammatory mediators, nosocomial infections and adverse effects of neuroprotective therapies increase the vulnerability of the lung to mechanical damage or ischemia-reperfusion insults, increasing the risk of subsequent lung damage [15].

In our study, selected apoptotic factors levels were lower in patients who died compared to survivors during admission to ICU. This relationship was reversed at day 3 and 7. The rapid increase of the expression of selected apoptotic proteins suggests an increased apoptosis rate after brain injury and precised a relationship between selected apoptotic protein levels in BALF and the hardness of injury.

Of course, an important aspect of this apoptotic activation is mechanical ventilation and oxygen administration. Brain damage impacts the mechanics of the respiratory system: elevated elastance and airway resistance, increased pulmonary hydrostatic pressures, endothelial permeability and as greater pulmonary inflammation as mentioned above [16, 17]. Certainly, mechanical ventilation in patients with brain injury is an unusual challenge. In clinical practice, ventilator settings should be focused on potential adverse effects and the interaction between mechanical ventilation, intracranial circulation and cerebral compliance or autoregulatory. The optimal strategy of mechanical ventilation is often unclear while avoiding intracranial hypertension and disturbance of cerebral blood flow (CBF) [18]. However, a protective ventilation strategy cannot be used halfway in patients with brain damage. The latest understanding proposes that this strategy may elevate neurophysiological protection [1, 19].

In addition, animal data has shown that lung slices cultured at 80% oxygen showed significantly stronger cell death activation, antioxidant transcription and acute inflammation [20]. In Our study both FiO2 and PaO2 at timepoints A, B, and C were statistically significantly lower in the survivor than in the non-survivor group of patients. This observation may be potentially the reason for higher activation of selected apoptotic factors. Recently, O2 toxicity has been a matter of concern, especially in regard to lungs and production of reactive oxygen species (ROS). Of late, the continuing discussion about the optimal dosing of oxygen in critically ill patients remains controversial. Of course, elevated FiO2 in acute brain injury improves brain tissue PbtO2 but importantly, incremental FiO2 elevated cerebral excitoxicity in severe brain damage [21, 22, 23].

It should be mentioned that both hyperoxia and hypoxia are associated with worse outcomes in patients with various types of brain injury [24, 25, 26]. In recent retrospective studies, hyperoxaemia was significantly associated with increased mortality and poor neurological outcomes [27]. In opposite, in mechanically ventilated patients with subarachnoid haemorrhage Lang et al. [28] did not find correlation between early moderate hyperoxaemia and outcome. Alali et al. [29] documented that PaO2 between 150–250 mmHg in the first 24 hours after TBI is associated with improvement of long- term functional outcomes. However, this study did exclude patients who died.

Our results join an extensive discussion with the recently published results whether normoxaemia or hyperoxaemia influence brain function and improve neurological recovery. Optimal PaO2 targets in daily clinical practise in brain injured patients are currently unknown.

Therefore, oxygen therapy in brain injured patients should be considered carefully, as both hyperoxia and hypoxia are connected with worse outcomes [4, 5]. Recent data suggest that the formation of reactive oxygen species (ROS), alterations of metabolic function disturbances, and hyperoxia-induced vasoconstriction are the main reasons for poorer outcomes. In contrast, some studies have documented that hyperoxia exposure presents even some benefits [6, 7]. Furthermore, concurrent polytrauma in TBI is also associated with greater systemic inflammation that can breach the blood-brain barrier (BBB) [30].

Decreased alveolar epithelial reliability predisposes to accumulation of oedemic fluid, rich in proteins and cellular material, in the interstitium and alveoli [31]. The management strategy of brain injury patients that aims to increase brain perfusion by fluid administration may worsen pulmonary function because of elevated EVLWI [32]. Several studies documented worse outcome in patients with increased EVLWI and pulmonary microvascular permeability showed as high PVPI [33, 34]. We found that the elevation of apoptotic molecules is statistically correlated with the increase of EVLWI and PVPI. A recent study has also demonstrated that high lung microvascular permeability in lung injury is correlated with the activation of apoptotic processes in the lungs [35, 36]. The endothelium defender p53 is involved in many respiratory pathologies such as acute lung injury, acute respiratory distress syndrome (ARDS), pulmonary arterial hypertension, pneumonia and tuberculosis [37, 38]. Brain injury has also been shown to be able to induce apoptosis of neurons by both p53 dependent and independent pathways [39]. In the case of failure of the p53 protective role, alternative apoptotic mechanisms are activated to enhance apoptosis. In addition, p53 participates in vascular homeostasis and probably in the optimal function of the alveolar-capillary membrane as the blood-air barrier. Importantly, the anti-inflammatory mechanism of p53 may pave the way for a possible therapeutic role in pulmonary diseases [40].

In summary, our results suggest that there is a close relationship between the injured brain and the lungs, that affects the apoptotic processes. The increased of apoptotic proteins in patients after injury, especially in the context of the initial clinical state, ultimately reflects the final outcome.

The lack of a clear mechanism of lung damage after brain injury indicates the complexity of the process and the need for further research. On the one hand, molecules released in the brain, BBB permeability, contribute to the activation of apoptosis processes in the lungs, on the other hand, treatment metods as oxygen supplementation may influences the clinical course after brain injury.

Further studies are required to analyse the transcriptional “software” controlling cell death signalling and lung-brain crosstalk. Thus, from a therapeutic perspective, the apoptotic activity modulators may present a new treatment option for brain injury and concomitant respiratory failure in this group of patients.

4.3 Limitations

This study has several limitations. The modest group of patients may be first and important limitation which significantly reduced the power of our statistical analysis. We also did not study a degree of apoptosis in mechanically ventilated patients without TBI. The degree of neutrophil apoptosis in BALF corresponds to high alveolar levels of chemokine IL-8 followed by increased level of the anti-inflammatory T-helper cytokine such as interleukin 10 [41]. Interestingly, the blockade of alveolar interleukin 10 leads to a lower apoptotic turnover of neutrophils [42]. This process can also be inhibited by dexmedetomidine [43] which is commonly used for sedation also in our patients. Also, massive inflammatory response following surgery- or trauma can dysregulate the pulmonary inflammatory balance intensifying cells apoptosis in alveolar fluid [44]. A lack of more comprehensive evaluation of the cellular components of BALF can also limit our analysis. Unfortunately, no proxility access to advanced laboratory procedures for 24 hours, limit immune cells evaluation.

5. Conclusions

This is first research providing the overview of selected apoptotic proteins concentrations and different apoptotic pathway disturbances in BALF in patients with brain injury. Our data suggest a nearby association between central nervous system injury, oxygen supplementation and apoptosis processes in the lungs, which corresponds to the severity of brain injury.

Availability of Data and Materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author Contributions

Study concept and design—DSG, WD, CR. Acquisition, analysis, or interpretation of data—DSG, ST, CR, KK, WD. Statistical analysis—DSG, CR. Tables and figures—DSG, WD. First draft of the article—DSG, ST. Critical revision for important intellectual content—DSG, WD, KK, AWZ, CR.

Ethics Approval and Consent to Participate

All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the Medical University in Lublin, Poland (KE-0254/210/2017).


Not applicable.


This research received no external funding.

Conflict of Interest

The authors declare no conflict of interest. Chiara Robba is serving as one of the Guest editors of this journal. We declare that Chiara Robba had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Gernot Riedel.

Picetti E, Pelosi P, Taccone FS, Citerio G, Mancebo J, Robba C, et al. VENTILatOry strategies in patients with severe traumatic brain injury: the VENTILO Survey of the European Society of Intensive Care Medicine (ESICM). Critical Care. 2020; 24: 158.
Mrozek S, Constantin J, Geeraerts T. Brain-lung crosstalk: Implications for neurocritical care patients. World Journal of Critical Care Medicine. 2015; 4: 163–178.
Spaite DW, Hu C, Bobrow BJ, Chikani V, Barnhart B, Gaither JB, et al. The Effect of Combined Out-of-Hospital Hypotension and Hypoxia on Mortality in Major Traumatic Brain Injury. Annals of Emergency Medicine. 2017; 69: 62–72.
Rincon F, Kang J, Maltenfort M, Vibbert M, Urtecho J, Athar MK, et al. Association between hyperoxia and mortality after stroke: a multicenter cohort study. Critical Care Medicine. 2014; 42: 387–396.
Brenner M, Stein D, Hu P, Kufera J, Wooford M, Scalea T. Association between early hyperoxia and worse outcomes after traumatic brain injury. Archives of Surgery. 2012; 147: 1042–1046.
Raj R, Bendel S, Reinikainen M, Kivisaari R, Siironen J, Lång M, et al. Hyperoxemia and long-term outcome after traumatic brain injury. Critical Care. 2013; 17: R177.
Roffe C, Nevatte T, Sim J, Bishop J, Ives N, Ferdinand P, et al. Effect of Routine Low-Dose Oxygen Supplementation on Death and Disability in Adults With Acute Stroke: The Stroke Oxygen Study Randomized Clinical Trial. The Journal of the American Medical Association. 2017; 318: 1125–1135.
Miñambres E, Ballesteros MA, Mayorga M, Marin MJ, Muñoz P, Figols J, et al. Cerebral apoptosis in severe traumatic brain injury patients: an in vitro, in vivo, and postmortem study. Journal of Neurotrauma. 2008; 25: 581–591.
Siwicka-Gieroba D, Terpilowska S, Robba C, Barud M, Kubik-Komar A, Dabrowski W. The Connection Between Selected Caspases Levels in Bronchoalveolar Lavage Fluid and Severity After Brain Injury. Frontiers in Neurology. 2022; 13: 796238.
Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991; 100: 1619–1636.
Carney N, Totten AM, O’Reilly C, Ullman JS, Hawryluk GWJ, Bell MJ, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2017; 80: 6–15.
Siwicka-Gieroba D, Malodobry K, Biernawska J, Robba C, Bohatyrewicz R, Rola R, et al. The Neutrophil/Lymphocyte Count Ratio Predicts Mortality in Severe Traumatic Brain Injury Patients. Journal of Clinical Medicine. 2019; 8: 1453.
Robba C, Bonatti G, Battaglini D, Rocco PRM, Pelosi P. Mechanical ventilation in patients with acute ischaemic stroke: from pathophysiology to clinical practice. Critical Care. 2019; 23: 388.
Sterclova M, Smetakova M, Stehlik L, Skibova J, Vasakova M. Bronchoalveolar lavage cell profiles and proteins concentrations can be used to phenotype extrinsic allergic alveolitis patients. Multidisciplinary Respiratory Medicine. 2019; 14: 13.
Pelosi P, Severgnini P, Chiaranda M. An integrated approach to prevent and treat respiratory failure in brain-injured patients. Current Opinion in Critical Care. 2005; 11: 37–42.
Bruni A, Garofalo E, Pelaia C, Longhini F, Navalesi P. Mechanical ventilation in brain injured patients: seeing the forest for the trees. Journal of Thoracic Disease. 2017; 9: 3483–3487.
Elmer J, Hou P, Wilcox SR, Chang Y, Schreiber H, Okechukwu I, et al. Acute respiratory distress syndrome after spontaneous intracerebral hemorrhage. Critical Care Medicine. 2013; 41: 1992–2001.
Oddo M, Citerio G. ARDS in the brain-injured patient: what’s different? Intensive Care Medicine. 2016; 42: 790–793.
Battaglini D, Siwicka Gieroba D, Brunetti I, Patroniti N, Bonatti G, Rocco PRM, et al. Mechanical ventilation in neurocritical care setting: A clinical approach. Best Practice & Research. Clinical Anaesthesiology. 2021; 35: 207–220.
Ruigrok MJR, Tomar J, Frijlink HW, Melgert BN, Hinrichs WLJ, Olinga P. The effects of oxygen concentration on cell death, anti-oxidant transcription, acute inflammation, and cell proliferation in precision-cut lung slices. Scientific Reports. 2019; 9: 16239.
Quintard H, Patet C, Suys T, Marques-Vidal P, Oddo M. Normobaric hyperoxia is associated with increased cerebral excitotoxicity after severe traumatic brain injury. Neurocritical Care. 2015; 22: 243–250.
Pascual JL, Georgoff P, Maloney-Wilensky E, Sims C, Sarani B, Stiefel MF, et al. Reduced brain tissue oxygen in traumatic brain injury: are most commonly used interventions successful? The Journal of Trauma. 2011; 70: 535–546.
Okonkwo DO, Shutter LA, Moore C, Temkin NR, Puccio AM, Madden CJ, et al. Brain Oxygen Optimization in Severe Traumatic Brain Injury Phase-II: A Phase II Randomized Trial. Critical Care Medicine. 2017; 45: 1907–1914.
Humaloja J, Skrifvars MB, Raj R, Wilkman E, Pekkarinen PT, Bendel S, et al. The Association Between Arterial Oxygen Level and Outcome in Neurocritically Ill Patients is not Affected by Blood Pressure. Neurocritical Care. 2021; 34: 413–422.
Li KC, Tam CWY, Shum H, Yan WW. Impact of Hyperoxia and Hypocapnia on Neurological Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study. Critical Care Research and Practice. 2019; 2019: 7584573.
Heinz UE, Rollnik JD. Outcome and prognosis of hypoxic brain damage patients undergoing neurological early rehabilitation. BMC Research Notes. 2015; 8: 243.
López HV, Vivas MF, Ruiz RN, Martínez JR, Navaridas BG, Villa MG, et al. Association between post-procedural hyperoxia and poor functional outcome after mechanical thrombectomy for ischemic stroke: an observational study. Annals of Intensive Care. 2019; 9: 59.
Lång M, Raj R, Skrifvars MB, Koivisto T, Lehto H, Kivisaari R, et al. Early Moderate Hyperoxemia Does Not Predict Outcome After Aneurysmal Subarachnoid Hemorrhage. Neurosurgery. 2016; 78: 540–545.
Alali AS, Temkin N, Vavilala MS, Lele AV, Barber J, Dikmen S, et al. Matching early arterial oxygenation to long-term outcome in severe traumatic brain injury: target values. Journal of Neurosurgery. 2019; 132: 537–544.
Liu H, He J, Wu Y, Du Y, Jiang Y, Chen C, et al. Endothelial Regulation by Exogenous Annexin A1 in Inflammatory Response and BBB Integrity Following Traumatic Brain Injury. Frontiers in Neuroscience. 2021; 15: 627110.
National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Matthay MA, Brower RG, Carson S, Douglas IS, Eisner M, et al. Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury. American Journal of Respiratory and Critical Care Medicine. 2011; 184: 561–568.
Tagami T, Nakamura T, Kushimoto S, Tosa R, Watanabe A, Kaneko T, et al. Early-phase changes of extravascular lung water index as a prognostic indicator in acute respiratory distress syndrome patients. Annals of Intensive Care. 2014; 4: 27.
Cecchetti C, Elli M, Stoppa F, Di Nardo M, Pasotti E, Gentile I, et al. Neurogenic pulmonary edema and variations of hemodynamic volumetric parameters in children following head trauma. Minerva Anestesiologica. 2013; 79: 1140–1146.
Monnet X, Anguel N, Osman D, Hamzaoui O, Richard C, Teboul J. Assessing pulmonary permeability by transpulmonary thermodilution allows differentiation of hydrostatic pulmonary edema from ALI/ARDS. Intensive Care Medicine. 2007; 33: 448–453.
Nanchal RS, Truwit JD. Recent advances in understanding and treating acute respiratory distress syndrome. F1000Research. 2018; 7: F1000 Faculty Rev-1322.
Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. The New England Journal of Medicine. 2017; 377: 562–572.
Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Experimental Cell Research. 2000; 256: 58–66.
Shetty SK, Tiwari N, Marudamuthu AS, Puthusseri B, Bhandary YP, Fu J, et al. p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis. The American Journal of Pathology. 2017; 187: 1016–1034.
Martin LJ, Kaiser A, Yu JW, Natale JE, Al-Abdulla NA. Injury-induced apoptosis of neurons in adult brain is mediated by p53-dependent and p53-independent pathways and requires Bax. The Journal of Comparative Neurology. 2001; 433: 299–311.
Kubra K, Akhter MS, Uddin MA, Barabutis N. P53 versus inflammation: an update. Cell Cycle. 2020; 19: 160–162.
Correction for Cekanaviciute et al., Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proceedings of the National Academy of Sciences of the United States of America. 2017; 114: E8943.
Melia D, Saha S. Abstracts of the 34th International Symposium on Intensive Care and Emergency Medicine, March 18–21, 2014, Brussels, Belgium. Critical Care. 2014; 18: P1–P502.
Hawkins RA, O’Kane RL, Simpson IA, Viña JR. Structure of the blood-brain barrier and its role in the transport of amino acids. The Journal of Nutrition. 2006; 136: 218S–226S.
Arand M, Melzner H, Kinzl L, Brückner UB, Gebhard F. Early inflammatory mediator response following isolated traumatic brain injury and other major trauma in humans. Langenbeck’s Archives of Surgery. 2001; 386: 241–248.

Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Back to top